Novel targeted therapies of bone tumors and future directions

[1]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[2]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[3]  H. West.  Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[6]  C. Porta,et al.  Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases , 2011, Journal of cellular physiology.

[7]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Jensen,et al.  The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. , 2010, Clinical breast cancer.

[9]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[10]  I. Tannock,et al.  Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  F. Saad,et al.  Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer , 2008, Cancer.

[13]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[14]  D. Heymann,et al.  RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.

[15]  B. Le Goff,et al.  DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.

[16]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[17]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[18]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[19]  D. Heymann.  Bisphosphonates and bone diseases: past, present and future. , 2010, Current pharmaceutical design.

[20]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.